MedTrace Logo

Focal Electrically Administered Seizure Therapy for the Treatment of Depression

NCT02462551 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-04-06

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and any possible side effects of focal electrically administered seizure therapy (FEAST) as a treatment intervention for patients with recurrent and treatment resistant depression.

Conditions

  • Treatment-Resistant Depression

Interventions

DEVICE

Focal Electrically Administered Seizure Therapy

A focal administration of the right unilateral configuration of electro-convulsive therapy for the treatment of recurrent and treatment-resistant depression.

Sponsors & Collaborators

  • Columbia University

    collaborator OTHER

  • MECTA corporation

    collaborator UNKNOWN

  • Medical University of South Carolina

    collaborator OTHER

  • Ziad Nahas

    lead OTHER

Principal Investigators

  • Ziad Nahas, MD, MSCR · American University of Beirut Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-10-31
Completion
2016-12-31

Countries

  • Lebanon

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462551 on ClinicalTrials.gov